Regenerative Medical Solutions Inc. (RMS)
Privately-owned company operating in Madison, Wisconsin (MG&E Innovation Center) and Chicago, Illinois. Team of experts in the field of stem cell research which allows RMS to make unprecedented scientific breakthroughs. Extensive experience in stem cell development, pancreatic islet biology, and islet transplantation. Broad business experience, with proven track record of entrepreneurship, product development, strategic growth, partnerships and corporate development. Collaborations with researchers at the University of Wisconsin Madison, national pharmaceutical companies, and international biotech companies.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
Regenerative Medical Solutions (RMS)
Regenerative Medical Solutions, Inc., is a start-up biotechnology company originating from Dr. Jon Odorico’s laboratory’s academic research at the University of Wisconsin. We were founded in 2012 with a vision to harness the regenerative property of human induced pluripotent stem cells (iPSCs) to produce pancreatic β (beta) islet cells to cure diabetes.
Our Story
Regenerative Medical Solutions (RMS), a privately-owned company operating near Madison, Wisconsin, has assembled a team of experts under the leadership of renowned stem cell researchers to develop a protocol to grow healthy and resilient
Mission & Vision
Diabetes is a major worldwide health concern that currently affects millions of people worldwide and places great financial burden on society. Further troubling is that its growth rate continues to skyrocket. Regenerative Medical Solutions (RMS), a Chicago and Madison-based company, was formed to combat these alarming trends in diabetes through the use of its stem cell derived Islet-Like Clusters (ILC) for dual use in drug discovery applications (screening, toxicity, efficacy testing) and direct therapeutic use targeting diabetes. We know many families are affected by diabetes, including our own, which is a significant motivation in our quest to find a cure.
Technology
Regenerative Medical Solutions (RMS) has developed a novel and proprietary technology to transform stem cells into insulin producing cells. Our pancreatic islet like cluster (ILC) cells are morphologically and functionally similar to β islet cells isolated from the human body. They contain glucagon producing alpha cells, somatostatin producing delta cells and insulin producing β islet cells.
We have leveraged our ILC technology to develop two product lines:
- ILC Cells– A specially formulated cryopreserved single cell ILC’s that can be used for diabetes research, drug discovery and toxicity testing.
- ILC cellular therapeutic candidate – Our diabetes cellular therapeutic that is under pre-clinical development.
RMS has built a substantial IP and know-how (trade secret) portfolio over the years in additional to exclusive and non-exclusive licensing of IP from academic institutions.
- Issued Patent (8,685,730): “Methods and Devices For Differentiating Pluripotent Stem Cells Into Cells Of The Pancreatic Lineage”
- Issued Patent (9,540,613 B2), RMS was a co-inventor with University of Wisconsin: “Methods For Producing Insulin-secreting Beta Cells From Human Pluripotent Stem Cells”
- Issued Patent (9,828,634): Markers for differentiation of stem cells into differentiated cell populations.
- Issued Patent (9,765,302): Compositions and methods for differentiating stem cells into cell. populations comprising beta-like cells.
- Non-exclusive license from Academia Japan to practice iPSC methods for both research tools and therapy.
Diabetes Background
Diabetes is the result of the pancreas producing too little or no insulin (Type 1 diabetes) or the failure of organs to respond to insulin properly which ultimately leads to beta cell exhaustion and demise (Type 2 diabetes) and is the world’s fastest growing disease. Diabetes represents a global health crisis with more than 400 million people across the world affected by it. It is estimated by the American Diabetes Association that one person is diagnosed with diabetes every 17 seconds and that every 6 seconds a person dies from diabetes. According to the Centers for Disease Control, one out of every three Americans will have type 2 diabetes by 2050, illustrating the urgency of a successful therapeutic for diabetes. As of 2018, approximately 34.2 million Americans (10.5% of the population) suffered from diabetes, resulting in direct medical costs of $237 billion. About 90-95% of 34.2 million Americans are affected by Type 2 Diabetes (T2D). Type 1 Diabetes (T1D) afflicts approximately 1.6 million Americans.
Unmet Needs In Diabetes Treatment
Although delivery of recombinant insulin is a life-saving therapy for many patients, it is imperfect. Fewer than 1 in 3 patients currently achieve recommended levels of blood glucose control resulting in diabetes-related complications. This lack of proper blood glucose control, even among patients with access to adequate diabetes care, underscores the fact that it is extraordinarily difficult for artificial systems such as insulin pumps and insulin injections to recapitulate the exquisite sensitivity and responsiveness of the body’s own insulin delivery system, the pancreatic beta cell. Therefore, replacement of the beta cells that are destroyed in T1D patients with beta cells from another source has remained a therapeutic goal of T1D therapy. It is well known that many patients with T2D ultimately develop exhausted beta cells which eventually die rendering the patient relatively insulin deficient. Increasingly pancreatic transplants are being performed for T2D across the US. Surgical β cell replacement treatments, such as pancreas or islet transplantation, supply functional β cells to effectively regulate blood glucose; yet, patients frequently suffer from surgical complications, immunological rejection, immunosuppressive medication side effects and toxicities, including cancer and infections. Furthermore, the current shortage of allogeneic pancreas and islets from cadaver organ donors severely limits the number of patients that can receive a transplant (<1000 per year in the US) and unfortunately fails to address the severe burden of this disease which afflicts hundreds of millions of patients. In conclusion, the unmet needs to manage, treat and cure diabetes are high and represent an opportunity for RMS to cure diabetes and become a successful biotechnology company that will continue to harness the power of stem cells for therapeutic applications.
Approaches To Cure
There are different approaches to treating diabetes, Pancreas transplant or use of existing pancreas cells through organ donation. While directly addressing the diabetes issue, the lack of organs available through donation, the cost, and uneven quality and yield of any one organ make this a limited option that fails to address the scope of the existing problem society faces today.
Extracting the body’s own cells, modifying them to produce insulin producing cells and then introducing them back into the patient provides therapy with predictable results at a lower cost. Since the patient’s own cells are utilized there are no availability or quality issues to consider. Introducing insulin producing beta cells derived from stem cells. This approach has not only ethical concerns in how the cells are produced, but introduces the ancillary problem of how to control the rejection issue of these cells by the patient’s immune system. An encapsulation device or immunosuppression drugs have to be used, complicating the procedure and raising questions as to the durability of the treatment.